JPWO2021118968A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021118968A5
JPWO2021118968A5 JP2022535127A JP2022535127A JPWO2021118968A5 JP WO2021118968 A5 JPWO2021118968 A5 JP WO2021118968A5 JP 2022535127 A JP2022535127 A JP 2022535127A JP 2022535127 A JP2022535127 A JP 2022535127A JP WO2021118968 A5 JPWO2021118968 A5 JP WO2021118968A5
Authority
JP
Japan
Prior art keywords
cancer
adc
seq
domain
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022535127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506158A5 (https=
JP2023506158A (ja
JP7679380B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/063732 external-priority patent/WO2021118968A1/en
Publication of JP2023506158A publication Critical patent/JP2023506158A/ja
Publication of JP2023506158A5 publication Critical patent/JP2023506158A5/ja
Publication of JPWO2021118968A5 publication Critical patent/JPWO2021118968A5/ja
Application granted granted Critical
Publication of JP7679380B2 publication Critical patent/JP7679380B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022535127A 2019-12-12 2020-12-08 Cd276に特異的な抗体-薬物コンジュゲートおよびその使用 Active JP7679380B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962947135P 2019-12-12 2019-12-12
US62/947,135 2019-12-12
PCT/US2020/063732 WO2021118968A1 (en) 2019-12-12 2020-12-08 Antibody-drug conjugates specific for cd276 and uses thereof

Publications (4)

Publication Number Publication Date
JP2023506158A JP2023506158A (ja) 2023-02-15
JP2023506158A5 JP2023506158A5 (https=) 2023-11-17
JPWO2021118968A5 true JPWO2021118968A5 (https=) 2023-11-17
JP7679380B2 JP7679380B2 (ja) 2025-05-19

Family

ID=74106168

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022535127A Active JP7679380B2 (ja) 2019-12-12 2020-12-08 Cd276に特異的な抗体-薬物コンジュゲートおよびその使用

Country Status (6)

Country Link
US (1) US20230032465A1 (https=)
EP (1) EP4041769A1 (https=)
JP (1) JP7679380B2 (https=)
AU (1) AU2020402752A1 (https=)
CA (1) CA3161573A1 (https=)
WO (1) WO2021118968A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024091979A1 (en) * 2022-10-24 2024-05-02 Brickbio, Inc. Cd276 (b7-h3) antibody-drug conjugates
WO2025103355A1 (zh) * 2023-11-14 2025-05-22 信达生物制药(苏州)有限公司 抗egfr和her3双特异性抗体-药物偶联物及其用途
WO2026011391A1 (en) * 2024-07-11 2026-01-15 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Anti-cd276 antibody, antibody-drug conjugate, and use thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
AU668384B2 (en) 1992-03-12 1996-05-02 Alkermes Controlled Therapeutics, Inc. Controlled release ACTH containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
KR100332254B1 (ko) 1993-10-01 2002-09-27 데이꼬꾸 조끼 세이야꾸 가부시키가이샤 신규인펩티드유도체
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
DE69930328T2 (de) 1998-08-27 2006-12-14 Spirogen Ltd., Ryde Dimere Pyrrolobenzodiazepine
DE60326060D1 (de) 2003-03-31 2009-03-19 Council Scient Ind Res Nichtvernetzende pyrroloä2,1-cüä1,4übenzodiazepine als potentielle antitumor-agentien und ihre herstellung
US7511032B2 (en) 2003-10-22 2009-03-31 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
GB0404577D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
JP5166861B2 (ja) 2004-03-09 2013-03-21 スピロゲン リミティッド ピロロベンゾジアゼピン
SI1813614T1 (sl) 2006-01-25 2012-01-31 Sanofi 174 Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate
ES2673822T3 (es) 2006-07-18 2018-06-25 Sanofi Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
PL2019104T3 (pl) 2007-07-19 2014-03-31 Sanofi Sa Środki cytotoksyczne obejmujące nowe pochodne tomaymycyny i ich zastosowanie terapeutyczne
CN102365021B (zh) 2009-02-05 2015-07-15 伊缪诺金公司 新型苯并二氮杂*衍生物
DK2528625T3 (da) 2010-04-15 2013-10-14 Spirogen Sarl Pyrrolobenzodiazepiner og konjugater deraf
MY168297A (en) 2011-11-17 2018-10-23 Pfizer Cytotoxic Peptides and Antibody Drug Conjugates Thereof
JP6613304B2 (ja) 2014-09-17 2019-12-04 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 抗cd276抗体(b7h3)
PE20240096A1 (es) 2015-10-02 2024-01-18 Hoffmann La Roche Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
EP3634485A4 (en) 2017-06-07 2021-07-21 Silverback Therapeutics, Inc. CONJUGATES OF ANTIBODIES CONTAINING IMMUNOMODULATOR COMPOUNDS AND THEIR USES
SG11201912010XA (en) * 2017-06-12 2020-01-30 Obsidian Therapeutics Inc Pde5 compositions and methods for immunotherapy

Similar Documents

Publication Publication Date Title
JP7330996B2 (ja) Cd73を標的とする抗体および抗体-薬物複合体、その製造方法と使用
JP7844591B2 (ja) バイパラトピックFR-α抗体及びイムノコンジュゲート
WO2019170131A1 (zh) 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
JP2018127469A5 (https=)
CN111110862A (zh) 抗cldn18.2抗体的药物偶联体及其制备方法和用途
JP2003523771A5 (https=)
JP2017535246A5 (https=)
CA2400868A1 (en) Anti-egfrviii scfvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
JP2016536020A5 (https=)
JP2015509947A5 (https=)
US20250034273A1 (en) Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof
JP2019205480A5 (https=)
JP2017524343A5 (https=)
JP2020528936A5 (https=)
TW202330618A (zh) 抗cdh6抗體及其抗體-藥物偶聯物
JPWO2021118968A5 (https=)
JPWO2022117040A5 (https=)
JP2026512687A (ja) ヒト化l1cam抗体-薬物複合体
JPWO2023028653A5 (https=)
JPWO2022188832A5 (https=)
RU2832083C2 (ru) Бипаратопные fr-альфа антитела и иммуноконъюгаты
CN114828887B (zh) 抗-αVβ6抗体和抗体-药物偶联物
IL312209A (en) Antibodies against CLDN18.2 and their uses
HK40130188A (zh) Cd38和icam1抗体及其用途
RU2025107388A (ru) Антитела к trop2/egfr и пути их применения